Skip to main content
AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.79%0700.HK-5.82%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.24%ORCL-0.97%3988.HK-0.36%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.17%0857.HK-2.43%UNH-10.21%1288.HK-1.64%PM-0.85%0005.HK-2.03%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.58%AUDUSD-1.47%EURAUD+0.95%AUDCAD-0.92%AUDCHF-0.90%GBPAUD+0.88%AUDNZD-0.88%NZDJPY-0.72%GBPJPY-0.70%CHFJPY-0.68%CADJPY-0.67%EURJPY-0.65%USDCHF+0.60%NZDUSD-0.59%GBPUSD-0.57%USDCAD+0.57%AUDSGD-0.56%EURUSD-0.52%AUDDKK-0.51%GBPTRY+0.41%AUDNOK-0.40%USDZAR+0.33%GBPHKD+0.32%NZDMXN+0.32%USDMXN+0.32%USDTHB+0.30%GBPMXN-0.28%EURZAR+0.24%GBPZAR+0.21%USDTRY+0.21%USDNOK+0.19%USDILS+0.16%CHFNOK+0.14%USDJPY-0.13%USDSEK+0.13%USDPLN+0.12%USDCNH-0.12%EURCNH-0.12%EURNOK+0.11%NOKJPY-0.10%EURHKD-0.09%USDDKK+0.08%CHFSEK+0.08%GBPSGD-0.08%EURCHF+0.07%SGDJPY+0.07%EURNZD+0.06%EURGBP+0.05%EURSGD-0.05%NZDSGD+0.05%EURSEK+0.05%NZDCAD-0.05%EURCZK+0.04%EURPLN+0.04%USDCOP-0.04%EURCAD+0.03%USDSGD+0.03%GBPCAD-0.03%CADCHF+0.03%PLNJPY-0.03%NZDCHF-0.02%CHFSGD-0.02%GBPCHF+0.02%GBPNZD+0.02%USDHKD-0.01%EURDKK0.00%UKOIL+0.52%W1-0.51%XNGUSD-0.46%C1-0.41%XPTUSD-0.38%USOIL+0.32%HG1-0.31%S1-0.22%GAUUSD-0.11%XAUUSD-0.11%COTTON+0.08%XAGUSD+0.06%BTCUSD-3.46%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.77%ZECUSDT-6.58%XMRUSDT-1.65%DOGEUSD+55.95%LINKUSD-3.12%XLMUSD-3.50%BCHUSDT-3.41%LTCUSD+47.50%UNIUSD-2.84%SUIUSD-2.76%TONUSD+59.18%HBARUSDT-4.95%TAOUSDT-2.97%AAVEUSD-3.45%ONDOUSDT-5.16%ICPUSDT-1.57%DOTUSDT-3.63%WLDUSDT-3.57%ARBUSDT-5.49%ATOMUSDT-2.24%INJUSDT-7.58%STXUSDT-2.75%PYTHUSDT-0.96%TIAUSDT-2.82%FETUSDT-4.16%JUPUSDT+0.63%SEIUSDT-4.48%GRTUSDT-3.22%OPUSDT-2.63%IOTAUSDT-2.46%POLUSDT-1.89%WIFUSDT-2.25%AXSUSDT-2.76%EOSUSDT-3.95%IMXUSDT-3.36%FARTCOINUSDT-6.28%GALAUSDT-1.65%DYDXUSDT-2.47%ORDIUSDT-2.25%NOTUSDT+0.86%RONINUSDT-2.92%AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.79%0700.HK-5.82%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.24%ORCL-0.97%3988.HK-0.36%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.17%0857.HK-2.43%UNH-10.21%1288.HK-1.64%PM-0.85%0005.HK-2.03%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.58%AUDUSD-1.47%EURAUD+0.95%AUDCAD-0.92%AUDCHF-0.90%GBPAUD+0.88%AUDNZD-0.88%NZDJPY-0.72%GBPJPY-0.70%CHFJPY-0.68%CADJPY-0.67%EURJPY-0.65%USDCHF+0.60%NZDUSD-0.59%GBPUSD-0.57%USDCAD+0.57%AUDSGD-0.56%EURUSD-0.52%AUDDKK-0.51%GBPTRY+0.41%AUDNOK-0.40%USDZAR+0.33%GBPHKD+0.32%NZDMXN+0.32%USDMXN+0.32%USDTHB+0.30%GBPMXN-0.28%EURZAR+0.24%GBPZAR+0.21%USDTRY+0.21%USDNOK+0.19%USDILS+0.16%CHFNOK+0.14%USDJPY-0.13%USDSEK+0.13%USDPLN+0.12%USDCNH-0.12%EURCNH-0.12%EURNOK+0.11%NOKJPY-0.10%EURHKD-0.09%USDDKK+0.08%CHFSEK+0.08%GBPSGD-0.08%EURCHF+0.07%SGDJPY+0.07%EURNZD+0.06%EURGBP+0.05%EURSGD-0.05%NZDSGD+0.05%EURSEK+0.05%NZDCAD-0.05%EURCZK+0.04%EURPLN+0.04%USDCOP-0.04%EURCAD+0.03%USDSGD+0.03%GBPCAD-0.03%CADCHF+0.03%PLNJPY-0.03%NZDCHF-0.02%CHFSGD-0.02%GBPCHF+0.02%GBPNZD+0.02%USDHKD-0.01%EURDKK0.00%UKOIL+0.52%W1-0.51%XNGUSD-0.46%C1-0.41%XPTUSD-0.38%USOIL+0.32%HG1-0.31%S1-0.22%GAUUSD-0.11%XAUUSD-0.11%COTTON+0.08%XAGUSD+0.06%BTCUSD-3.46%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.77%ZECUSDT-6.58%XMRUSDT-1.65%DOGEUSD+55.95%LINKUSD-3.12%XLMUSD-3.50%BCHUSDT-3.41%LTCUSD+47.50%UNIUSD-2.84%SUIUSD-2.76%TONUSD+59.18%HBARUSDT-4.95%TAOUSDT-2.97%AAVEUSD-3.45%ONDOUSDT-5.16%ICPUSDT-1.57%DOTUSDT-3.63%WLDUSDT-3.57%ARBUSDT-5.49%ATOMUSDT-2.24%INJUSDT-7.58%STXUSDT-2.75%PYTHUSDT-0.96%TIAUSDT-2.82%FETUSDT-4.16%JUPUSDT+0.63%SEIUSDT-4.48%GRTUSDT-3.22%OPUSDT-2.63%IOTAUSDT-2.46%POLUSDT-1.89%WIFUSDT-2.25%AXSUSDT-2.76%EOSUSDT-3.95%IMXUSDT-3.36%FARTCOINUSDT-6.28%GALAUSDT-1.65%DYDXUSDT-2.47%ORDIUSDT-2.25%NOTUSDT+0.86%RONINUSDT-2.92%
AB

Arcutis Biotherapeutics, Inc. (ARQT)

NASDAQ • Healthcare

$27.61
+$0.28 (+1.0%)
Market closed

Last close at November 18, 2026 at 21:00 UTC

Open$27.31
Day Range$27.1 - $27.8
Avg. Volume (3M)2.1M
Market Cap$3.4B
P/E Ratio120.0
52 Week Range
$19.3$34.8

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$143.9M100%
Gross Profitminus cost of goods$131.4M91%
Operating Incomeminus R&D and overhead$9.4M7%
Net Incomeminus taxes and the rest$8.8M6%

In plain terms: out of every $100 in revenue, Arcutis Biotherapeutics, Inc. keeps $6 as net profit.

Fundamentals & Financials

Revenue (TTM)
$508.6M
Net Income (TTM)
$29.9M
EPS (TTM)
$0.23
ROA (TTM)
5.7%
Current Ratio
2.92

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-350.0%Q2 2026-$0.09
+99.7%Q3 2026$0.11
-66.7%Q4 2026$0.06

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Miss -66.7%

Arcutis Biotherapeutics’ EPS trailed consensus even as revenue came in line, as the company posted the third fiscal quarter of 2026 results on November 4, 2026 with revenue up 45.1% year over year to about $143.9 million (up from roughly $99.2 million a year ago). EPS of $0.06 trailed the $0.18 estimate (-66.7%), while revenue of $143.9 million was in line with the $142.6 million estimate (+0.9%). Profitability stayed high, with gross profit of about $131.5 million translating to a gross margin near 91%, and operating income of roughly $9.4 million for an operating margin around 7%. Net income rose 18.8% from a year ago to about $8.8 million (versus roughly $7.4 million a year ago), and the quarter generated operating cash flow of about $18.9 million. For the next period, consensus calls for EPS of $0.22 on revenue of $160.7 million.

View full earnings history

About Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. develops and markets therapies for skin-related diseases and operates as a biotechnology company listed on the NASDAQ under ARQT. In FY2025, the company generated $376.1 million in revenue. Formerly known as Arcutis, Inc., it focuses on dermatology products and pipeline programs built around inflammatory skin conditions.

Name
Arcutis Biotherapeutics, Inc.
CEO
Todd Franklin Watanabe
Industry
Healthcare
Year Founded
2016
Employees
354

Today's Snapshot

AI-generated

The day ended with ARQT 1% higher at 27.61, outperforming a weaker sector. Volume was about a third of its usual level.

Trading Volume

Below 10d avg (2.5M)

835.3K

vs S&P 500 Today

Outperforming Market

+1.28%

Updated: November 18, 2026 at 21:30 UTC

Technical Indicators

2 Buy2 Neutral4 Sell
At 27.61 the stock sits near its short-term pivot and close to the ten-day simple average while remaining below key medium-term averages, signaling mixed price structure against a still-below-200-day backdrop. Momentum measures are negative, with MACD and short-term momentum both tilting bearish, and ADX around twenty suggests trend weakness rather than conviction. Volatility is elevated, with an ATR near 1.6 indicating outsized moves, while on-balance volume shows recent accumulation despite the price weakness. Technical takeaway: Sell.
All signals
  • EMA (5 indicators)$26.51 - $28.51
    Sell
  • RSI (14)46.65
    Neutral
  • Stochastic %K (14, 3, 3)22.29
    Neutral
  • MACD Level (12, 26)-0.32
    Sell

Peers & Related Assets

ALDXAldeyra The
$0.67-3.3%
ACRSAclaris Therapeutics, Inc.
EVMNEvommune, Inc.
TTRXTurn Therapeutics Inc.
SLGLSol-Gel Technologies Ltd.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.